WorldPing logo WorldPing← All news

Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production

Written and edited by the WorldPing NewsdeskPublished Updated Original reporting: CNBC

What happened

Eli Lilly is trying to catch up in the GLP-1 pill market to Novo, which got a head start in the space.

Key facts

  • Eli Lilly is trying to catch up in the GLP-1 pill market to Novo, which got a head start in the space.
  • Reported by CNBC and published Mon, 21 Sep 2026 18:57:34 UTC.

Why it matters

Economic releases and corporate results feed directly into rate expectations, currency moves and equity pricing, so the detail here often matters more to markets than the headline itself.

What to watch next

  • Revisions to the initial figures once fuller data is released
  • How rate expectations and index futures respond
  • Guidance or commentary from the companies and policymakers involved

Coverage timeline

When each newsroom published on this story, oldest first — all times UTC.

  1. Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production

  2. ‘You’re a going to be a great one’: Trump tells Mamdani he has ‘potential’ to be a great mayor and floats federal funds to his native Queens

Sources

The original report was published by CNBC. WorldPing does not claim that reporting — this page summarises and contextualises it.

Read the full report at CNBC

Related WorldPing coverage

What the equinox 'henge' effect tells us about U.S. citiesWorldPing
NPR Top

What the equinox 'henge' effect tells us about U.S. cities

The fall equinox, which arrives Tuesday in the U.S., brings shorter days, and chances to witness alignment between Earth and the sun. It's a modern version of ancient observances of a celestial shift.

Brief by WorldPing · Original reporting by NPR Top